Want to see ISPC full AI Analyst Report?
ISPC Stock Chart & Stats
$0.31
-$0.03(-1.03%)
At close: 4:00 PM EST
$0.31
-$0.03(-1.03%)
Day’s Range― - ―
52-Week Range$1.77 - $127.20
Previous CloseN/A
Volume25.67K
Average Volume (3M)8.88M
Market Cap
$2.88M
Enterprise Value$5.03
Total Cash (Recent Filing)$2.82M
Total Debt (Recent Filing)$254.99K
Price to Earnings (P/E)―
Beta1.39
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,522,359
10 Day Avg. Volume698,577
30 Day Avg. Volume8,882,166
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)0.62
P/FCF Ratio-0.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform / Digital TransformationCompleting Milestone 3 is a durable operational upgrade: expanded marketplace features, deeper partner integrations and geographic rollout improve matching, scaling and supplier participation, which can raise order throughput and long-term platform competitiveness.
Low Financial LeverageVery low debt relative to equity limits interest burden and preserves borrowing capacity. This structural leverage position gives management flexibility to fund execution or weather downturns without heavy fixed financing costs, supporting longer runway for strategic initiatives.
Access To Capital / FinancingA publicly placed offering and recent private placement demonstrate continued access to investors and capital markets. Fresh proceeds and use of a placement agent provide near-term runway to fund operations and platform expansion, reducing immediate liquidity stress for several months.
Bears Say
Severe Revenue Decline And LossesSteep top-line contraction and extremely negative margins indicate the core marketplace is struggling to monetize at scale. Persistent revenue declines shrink operating leverage, hinder reinvestment capacity, and make durable profitability dependent on material and sustained demand recovery.
Persistent Cash BurnConsistent negative operating and free cash flow means the company cannot self-fund growth or cover losses. Ongoing burn forces repeated capital raises, raises dilution risk, constrains long-term investment in sales/tech, and increases vulnerability to funding market shifts.
Nasdaq Noncompliance And Dilution RiskFailure to meet minimum equity standards threatens listing continuity and creates urgency to recapitalize. That structural pressure often leads to dilutive financings or restrictive covenants, undermining long-term investor confidence and raising the cost of capital for strategic plans.
iSpecimen News
ISPC FAQ
What was iSpecimen’s price range in the past 12 months?
iSpecimen lowest stock price was $1.77 and its highest was $127.20 in the past 12 months.
What is iSpecimen’s market cap?
iSpecimen’s market cap is $2.88M.
When is iSpecimen’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were iSpecimen’s earnings last quarter?
Currently, no data Available
Is iSpecimen overvalued?
According to Wall Street analysts iSpecimen’s price is currently Overvalued.
Does iSpecimen pay dividends?
iSpecimen does not currently pay dividends.
What is iSpecimen’s EPS estimate?
iSpecimen’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does iSpecimen have?
iSpecimen has 1,522,359 shares outstanding.
What happened to iSpecimen’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of iSpecimen?
Currently, no hedge funds are holding shares in ISPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
iSpecimen
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that strategically links medical researchers requiring access to subjects, samples, and pertinent data with organizations that hold these invaluable resources. iSpecimen's clientele primarily includes biopharmaceutical firms, in vitro diagnostics companies, and governmental and academic research institutions. The company, established in 2009, is headquartered in Lexington, Massachusetts.
Technical Analysis
―
Intelligent Bio Solutions
―
BioNexus Gene Lab Corp
―
―
bioAffinity Technologies, Inc.
―
Ownership Overview
―
Insiders
4.17% Mutual Funds
― Other Institutional Investors
95.82% Public Companies and
Individual Investors